| abstract |
The disclosure relates to monoclonal antibodies immunoreactive with specific cells of the myeloid lineage of the hematopoietic system, hybridomas producing the antibodies, and methods of using the antibodies, particularly as therapeutic treatments for conditions or diseases involving progenitor cells of the myeloid lineage. |